CN102676650A - Cpt1a基因或蛋白的定量检测在食管鳞癌预后判断中的应用 - Google Patents
Cpt1a基因或蛋白的定量检测在食管鳞癌预后判断中的应用 Download PDFInfo
- Publication number
- CN102676650A CN102676650A CN201210058744XA CN201210058744A CN102676650A CN 102676650 A CN102676650 A CN 102676650A CN 201210058744X A CN201210058744X A CN 201210058744XA CN 201210058744 A CN201210058744 A CN 201210058744A CN 102676650 A CN102676650 A CN 102676650A
- Authority
- CN
- China
- Prior art keywords
- cpt1a
- detection
- quantitative
- squamous cell
- esophageal squamous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 title claims abstract description 61
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 title claims abstract description 60
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 title claims abstract description 60
- 101150073133 Cpt1a gene Proteins 0.000 title claims abstract description 57
- 238000001514 detection method Methods 0.000 title claims abstract description 54
- 238000004393 prognosis Methods 0.000 title claims abstract description 34
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 23
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 46
- 230000014509 gene expression Effects 0.000 claims abstract description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 claims description 31
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 claims description 31
- 238000012360 testing method Methods 0.000 claims description 17
- 238000012151 immunohistochemical method Methods 0.000 claims description 15
- 108091034117 Oligonucleotide Proteins 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 14
- 239000000523 sample Substances 0.000 claims description 14
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 13
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 13
- 238000003753 real-time PCR Methods 0.000 claims description 10
- 238000013016 damping Methods 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 230000002980 postoperative effect Effects 0.000 abstract description 7
- 230000002018 overexpression Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 11
- 238000011529 RT qPCR Methods 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 102000018832 Cytochromes Human genes 0.000 description 6
- 108010052832 Cytochromes Proteins 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 5
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 101150112014 Gapdh gene Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000909313 Homo sapiens Carnitine O-palmitoyltransferase 2, mitochondrial Proteins 0.000 description 2
- 101000989606 Homo sapiens Cholinephosphotransferase 1 Proteins 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001921 nucleic acid quantification Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 101100008048 Caenorhabditis elegans cut-4 gene Proteins 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
- 102100027947 Carnitine O-palmitoyltransferase 1, muscle isoform Human genes 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 101000859574 Homo sapiens Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012916 chromogenic reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210058744.XA CN102676650B (zh) | 2011-03-09 | 2012-03-08 | Cpt1a基因或蛋白的定量检测在食管鳞癌预后判断中的应用 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110054980.X | 2011-03-09 | ||
CN201110054980 | 2011-03-09 | ||
CN201110054980X | 2011-03-09 | ||
CN201210058744.XA CN102676650B (zh) | 2011-03-09 | 2012-03-08 | Cpt1a基因或蛋白的定量检测在食管鳞癌预后判断中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102676650A true CN102676650A (zh) | 2012-09-19 |
CN102676650B CN102676650B (zh) | 2015-08-05 |
Family
ID=46809200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210058744.XA Expired - Fee Related CN102676650B (zh) | 2011-03-09 | 2012-03-08 | Cpt1a基因或蛋白的定量检测在食管鳞癌预后判断中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102676650B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104878120A (zh) * | 2015-06-26 | 2015-09-02 | 济南市儿童医院 | 一种检测cpt1b基因突变的引物及试剂盒 |
CN104894126A (zh) * | 2015-06-23 | 2015-09-09 | 济南市儿童医院 | 一种检测cpt-ⅱ基因突变的引物及试剂盒 |
CN105063215A (zh) * | 2015-08-19 | 2015-11-18 | 济南市儿童医院 | 用于检测cpt1a基因突变的引物及试剂盒 |
CN105112515A (zh) * | 2015-08-14 | 2015-12-02 | 深圳市众偱精准医学研究院 | Fbxw7基因及表达产物在肾癌检测、肾癌药物制备中的用途 |
CN111128385A (zh) * | 2020-01-17 | 2020-05-08 | 河南科技大学第一附属医院 | 一种用于食管鳞癌的预后预警系统及其应用 |
CN115341037A (zh) * | 2021-09-14 | 2022-11-15 | 北京大学第三医院(北京大学第三临床医学院) | 一种人脂肪酸代谢关键酶基因检测方法以及试剂盒 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1556413A (zh) * | 2004-01-08 | 2004-12-22 | 中南大学湘雅医学院肿瘤研究所 | 一种用于肿瘤早期诊断的组织芯片及制备器具 |
CN1618985A (zh) * | 2003-11-21 | 2005-05-25 | 中国医学科学院肿瘤医院肿瘤研究所 | 一个新的食管癌标志基因rpl14及其用途 |
-
2012
- 2012-03-08 CN CN201210058744.XA patent/CN102676650B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1618985A (zh) * | 2003-11-21 | 2005-05-25 | 中国医学科学院肿瘤医院肿瘤研究所 | 一个新的食管癌标志基因rpl14及其用途 |
CN1556413A (zh) * | 2004-01-08 | 2004-12-22 | 中南大学湘雅医学院肿瘤研究所 | 一种用于肿瘤早期诊断的组织芯片及制备器具 |
Non-Patent Citations (3)
Title |
---|
NAN HU等: "Genomic characterization of esophageal squamous cell carcinoma from a high-risk population in China", 《CANCER RES.》 * |
SHIGEO HIRASAKI等: "BAC Clones Related to Prognosis in Patients with Esophageal Squamous Carcinoma: An Array Comparative Genomic Hybridization Study", 《THE ONCOLOGIST》 * |
史志周: "食管鳞癌基因组改变及预后相关基因的研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104894126A (zh) * | 2015-06-23 | 2015-09-09 | 济南市儿童医院 | 一种检测cpt-ⅱ基因突变的引物及试剂盒 |
CN104878120A (zh) * | 2015-06-26 | 2015-09-02 | 济南市儿童医院 | 一种检测cpt1b基因突变的引物及试剂盒 |
CN105112515A (zh) * | 2015-08-14 | 2015-12-02 | 深圳市众偱精准医学研究院 | Fbxw7基因及表达产物在肾癌检测、肾癌药物制备中的用途 |
CN105063215A (zh) * | 2015-08-19 | 2015-11-18 | 济南市儿童医院 | 用于检测cpt1a基因突变的引物及试剂盒 |
CN105063215B (zh) * | 2015-08-19 | 2017-07-07 | 济南市儿童医院 | 用于检测cpt1a基因突变的引物及试剂盒 |
CN111128385A (zh) * | 2020-01-17 | 2020-05-08 | 河南科技大学第一附属医院 | 一种用于食管鳞癌的预后预警系统及其应用 |
CN111128385B (zh) * | 2020-01-17 | 2020-11-10 | 河南科技大学第一附属医院 | 一种用于食管鳞癌的预后预警系统及其应用 |
CN115341037A (zh) * | 2021-09-14 | 2022-11-15 | 北京大学第三医院(北京大学第三临床医学院) | 一种人脂肪酸代谢关键酶基因检测方法以及试剂盒 |
CN115341037B (zh) * | 2021-09-14 | 2023-09-26 | 北京大学第三医院(北京大学第三临床医学院) | 一种人脂肪酸代谢关键酶基因检测方法以及试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN102676650B (zh) | 2015-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Oue et al. | High miR‐21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer | |
CN102676650A (zh) | Cpt1a基因或蛋白的定量检测在食管鳞癌预后判断中的应用 | |
CA2623775A1 (en) | Methods and materials for identifying the origin of a carcinoma of unknown primary origin | |
Cho-Vega | A diagnostic algorithm for atypical spitzoid tumors: guidelines for immunohistochemical and molecular assessment | |
WO2011133981A1 (en) | Test for the detection of bladder cancer | |
US20110070582A1 (en) | Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects | |
Song et al. | High expression of FOXR2 in breast cancer correlates with poor prognosis | |
Sun et al. | Diagnostic and prognostic value of microRNAs in cholangiocarcinoma: a systematic review and meta-analysis | |
He et al. | Expression of nestin in ovarian serous cancer and its clinicopathologic significance. | |
CN104263815A (zh) | 一组用于激素受体阳性乳腺癌预后的基因及其应用 | |
Carbone et al. | Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists | |
CN107177683A (zh) | 一种膀胱癌筛选检测试剂盒 | |
Wang et al. | Prognostic value of SOX2, Cyclin D1, P53, and ki-67 in patients with esophageal squamous cell carcinoma | |
Scabini et al. | The effect of preoperative chemoradiotherapy on lymph nodes harvested in TME for rectal cancer | |
CN104711341A (zh) | Dlk1基因在制备胃肠道间质瘤诊断试剂中的应用 | |
CN108398556A (zh) | 用于肝癌切除术后预后的双抗体联合荧光检测试剂盒 | |
Yu et al. | Systematic re‑analysis strategy of serum indices identifies alkaline phosphatase as a potential predictive factor for cervical cancer | |
Kosari et al. | Shared gene expression alterations in prostate cancer and histologically benign prostate from patients with prostate cancer | |
Khan et al. | Potential plasma microRNAs signature miR-190b-5p, miR-215-5p and miR-527 as non-invasive biomarkers for prostate cancer | |
Verga et al. | Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia? | |
CN106319062B (zh) | 一种用于甲状腺癌辅助诊断或疗效预测的微创试剂盒 | |
Chen et al. | cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer | |
Saggiorato et al. | Absence of RET gene point mutations in sporadic thyroid C-cell hyperplasia | |
CN115449555B (zh) | Adgra2作为乳腺癌化疗疗效和预后评价生物标志物的应用 | |
Sato et al. | Correlation of clinicopathological features and LGR5 expression in colon adenocarcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TUMOR HOSPITAL, CHINESE MEDICAL ACADEMY Free format text: FORMER OWNER: TUMOUR INST., CHINA MEDICAL SCIENCE RESEARCH ACADEMY Effective date: 20150811 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150811 Address after: 100021 Beijing, Panjiayuan, South Lane, No. 17, No. Patentee after: CANCER HOSPITAL, CHINESE ACEDEMY OF MEDICAL SCIENCES Address before: 100021 Beijing, Panjiayuan, South Lane, No. 17, No. Patentee before: CANCER INSTITUTE, CHINESE ACADEMY OF MEDICAL SCIENCES |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150805 |
|
CF01 | Termination of patent right due to non-payment of annual fee |